The clinical case for proton beam therapy

Robert L. Foote, Scott L. Stafford, Ivy A. Petersen, Jose S. Pulido, Michelle J. Clarke, Steven E. Schild, Yolanda I. Garces, Kenneth R. Olivier, Robert C. Miller, Michael G. Haddock, Elizabeth Yan, Nadia N. Laack, Carola A.S. Arndt, Steven J. Buskirk, Vickie L. Miller, Christopher R. Brent, Jon J. Kruse, Gary A. Ezzell, Michael G. Herman, Leonard L. GundersonCharles Erlichman, Robert B. Diasio

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.Proton beam therapy is a technically advanced and promising form of radiation therapy.

Original languageEnglish (US)
Article number174
JournalRadiation Oncology
Issue number1
StatePublished - Oct 22 2012


  • Clinical review
  • Neoplasms
  • Proton beam therapy
  • X-ray therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'The clinical case for proton beam therapy'. Together they form a unique fingerprint.

Cite this